Halozyme Therapeutics, Inc. (BMV:HALO)

Market Cap	137.61B
Revenue (ttm)	22.16B
Net Income (ttm)	9.92B
Shares Out	n/a
EPS (ttm)	76.83
PE Ratio	13.87
Forward PE	9.74
Dividend	n/a
Ex-Dividend Date	n/a

Volume	500
Average Volume	767
Open	1,114.38
Previous Close	n/a
Day's Range	1,114.38 - 1,121.86
52-Week Range	954.15 - 1,121.86
Beta	n/a
RSI	n/a
Earnings Date	Aug 5, 2025

About Augmedix

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States and internationally. The company’s products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the disper...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1998
• Employees: 350
• Stock Exchange: Mexican Stock Exchange
• Ticker Symbol: HALO

Financial Performance

In 2024, Halozyme Therapeutics's revenue was $1.02 billion, an increase of 22.44% compared to the previous year's $829.25 million. Earnings were $444.09 million, an increase of 57.71%.